Persistence and discontinuation of adjuvant endocrine therapy in women with breast cancer

详细信息    查看全文

• 作者：Sayaka Kuba ; Mayumi Ishida ; Yoshiaki Nakamura ; Kenichi Taguchi…
• 关键词：Adjuvant endocrine therapy ; Breast cancer ; Discontinuation
• 刊名：Breast Cancer
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：23
• 期：1
• 页码：128-133
• 全文大小：399 KB
• 参考文献：1.Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–84.PubMed CrossRef
  2.Mann BS, Johnson JR, Kelly R, Sridhara R, Williams G, Pazdur R, et al. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen. Clin Cancer Res. 2005;11(16):5671–7.PubMed CrossRef
  3.Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst. 2007;99(24):1845–53.PubMed CrossRef
  4.Mamounas EP, Jeong JH, Wickerham DL, Smith RE, Ganz PA, Land SR, et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol. 2008;26(12):1965–71.PubMed CrossRef
  5.Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805–16.
  6.Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60–2.PubMed CrossRef
  7.Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349(19):1793–802.PubMed CrossRef
  8.Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350(11):1081–92.PubMed CrossRef
  9.van de Water W, Bastiaannet E, Hille ET, Meershoek-Klein Kranenbarg EM, Putter H, Seynaeve CM, et al. Age-specific nonpersistence of endocrine therapy in postmenopausal patients diagnosed with hormone receptor-positive breast cancer: a TEAM study analysis. Oncologist. 2012;17(1):55–63.PubMed PubMedCentral CrossRef
  10.Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA. Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat. 2006;99(2):215–20.PubMed CrossRef
  11.McCowan C, Shearer J, Donnan PT, Dewar JA, Crilly M, Thompson AM, et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer. 2008;99(11):1763–8.PubMed PubMedCentral CrossRef
  12.Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnin-Alibozec A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008;26(4):556–62.PubMed CrossRef
  13.Owusu C, Buist D, Field TS, Lash TL, Thwin SS, Geiger AN, et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2008;26(4):549–55.PubMed CrossRef
  14.van Herk-Sukel MP, van de Poll-Franse LV, Voogd AC, Nieuwenhuijzen GA, Coebergh JW, Herings RM. Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. Breast Cancer Res Treat. 2010;122(3):843–51.PubMed CrossRef
  15.Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010;28(27):4120–8.PubMed PubMedCentral CrossRef
  16.Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126(2):529–37.PubMed PubMedCentral CrossRef
  17.Guth U, Myrick ME, Kilic N, Eppenberger-Castori S, Schmid SM. Compliance and persistence of endocrine adjuvant breast cancer therapy. Breast Cancer Res Treat. 2012;131(2):491–9.PubMed CrossRef
  18.Wigertz A, Ahlgren J, Holmqvist M, Fornnder T, Adolfsson J, Lindman H, et al. Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study. Breast Cancer Res Treat. 2012;133(1):367–73.PubMed CrossRef
  19.Wigertz A, Ahlgren J, Holmqvist M, Fornander T, Adolfsson J, Lindman H, et al. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol. 2012;30(9):936–42.CrossRef
  20.Rae JM, Sikora MJ, Henry NL, Li L, Kim S, Oesterreich S, et al. Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J. 2009;9(4):258–64.PubMed PubMedCentral CrossRef
  21.Thompson AM, Johnson A, Quinlan P, Hillman G, Fontecha M, Bray SE, et al. Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat. 2011;125(1):279–87.PubMed CrossRef
  22.Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat. 2012;134(2):459–78.PubMed PubMedCentral CrossRef
  23.Dezentie VO, Blijderveen N, Gelderblom H, Putter H, Herk-Sukel M, Casparie MK, et al. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol. 2010;28(14):2423–9.CrossRef
  24.Duijts SF, van Beurden M, Oldenburg HS, Hunter MS, Kieffer JM, Stuiver MM, et al. Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. J Clin Oncol. 2012;30(33):4124–33.PubMed CrossRef
  25.Cuzick J, Sestak I, Cella D, Fallowfield L, ATAC Trialists’ Group. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol. 2008;9(12):1143–8.PubMed CrossRef
  26.Wouters H, Maatman GA, Van Dijk L, Bouvy ML, Vree R, Van Geffen EC, et al. Trade-odd preferences regarding adjuvant endocrine therapy among women with estrogen receptor-positive breast cancer. Ann Oncol. 2013;24(9):2324–9.
  27.Hadji P, Blettner M, Harbeck N, Jackisch C, Lück HJ, Windemuth-Kieselbach C, et al. The Patient’s anastrozole compliance to therapy (PACT) program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer. Ann Oncol. 2013;24(6):1505–12.PubMed CrossRef
  
• 作者单位：Sayaka Kuba (1) (3)
  Mayumi Ishida (1)
  Yoshiaki Nakamura (1)
  Kenichi Taguchi (2)
  Shinji Ohno (1)
  
  1. Department of Breast Oncology, National Hospital Organization, Kyushu Cancer Center, Kyushu, Japan
  3. Department of Surgery, Nagasaki University, 1-7-1 Sakamoto-machi, Nagasaki, Nagasaki, 852-8501, Japan
  2. Department of Pathology, National Hospital Organization, Kyushu Cancer Center, Kyushu, Japan
  
• 刊物主题：Surgical Oncology; Oncology; Surgery; Cancer Research;
• 出版者：Springer Japan
• ISSN：1880-4233

文摘

Aims Although 8–73 % of breast cancer patients who receive adjuvant endocrine therapy discontinue it, discontinuation is little studied in Asian breast cancer patients.